Regulatory, ethical and legal issues in biotechnologySemester 2 2012ChemTech Case study
(Draft)Development of an avian flu vaccine for the Australian poultry industryThe companyChemTech is a successful biotechnology company developing and manufacturing veterinary small molecule anti-infective drugs for production animals.
The company has decided to move into the development of recombinant vaccines for the treatment of respiratory diseases in intensively reared pigs and poultry. The company’s first project will be the development of a recombinant flu vaccine to treat avian influenza A (AIA) for the poultry industry in Australia. The company intends to develop the recombinant vaccine in house and outsource vaccine manufacture to Bioproperties Pty Ltd and field testing in a commercial hatchery (Baiada Poultry) under a collaborative research agreement with the Poultry Cooperative Research Centre Poultry Hub.
Company capabilitiesChemTech supports an active R&D section with expertise in chemical synthesis and analytical chemistry, microbiology and small molecule drug development and testing
in vitroand
in vivo. The company has laboratory facilities for chemistry, microbiology and cell culture and an animal facility capable of handling small animals and birds. It intends to establish capabilities for genetic engineering.
The AIA vaccine projectThe company proposes to develop a human recombinant adenovirus serotype 5 (AD5) vector encoding the haemagglutinin (HA) genes of pathogenic H5 or H7 AIA serotypes. The vaccine will be injected into chick eggs. The project has the following stages
In house laboratory studies (ChemTech)1 Development and in vitro evaluation of the vaccine construct1.1 Construction of replication-incompetent AD5 vector with H5 or H7 gene inserts1.1.1 PCR-amplification of H5 or H7 genes from a plasmid template using suitable primer pairs
1.1.2 Insertion of the HA gene into the shuttle plasmid (pAdApt) to generate a plasmid with H5 or H7 gene (pH5/H7) and human CMV early promoter
1.2 Construction of the recombinant Ad5 vector (Ad5-H5/H7)1.2.1 Co-transfection of human PER. C6 cells (Crucell) with the plasmid (pH5/H7) and the AdEasy™ adenoviral vector system.
1.2.2 Separation of Ad5 vector clone by plaque assays
1.2.3 Validation of the construct by DNA sequencing
1.2.4 Titration (ifu/mL) by the Adeno-X rapid titer kit
1.2.5 stability & cell location of vector
2 Antibody production in chicks2.1 Vaccination
by
automated injectionof single-doses of vaccine (10
6to 10
10infectious units) into specific-pathogen-free (
SPF) chicken eggs at day 18 of incubation (SPAFAS Australia Pty Ltd). SPF eggs meet European Pharmacopoeia SPF requirements.
2.2 Evaluation of antibody response2.2.1 Determination of percent of chicks showing seroconversion at 21 and 42 days after hatch
HI inhibition or agar gel immunodiffusion (AGID) determination of antibody titres in serum samples from individual chickens against a pathogenic H5 or H7 strain.
2.2.2 Determination of effective vaccination infection dose
2.3.2 Characterisation of antibody binding (affinity, avidity, specificity & cross reactivity) to homologous AI strains using standard tests
3 Demonstration of protective efficacy by AI challenge3.1 Challenge of cohorts of vaccinated and un-vaccinated SPF chicks hatched from bought-in SPC eggs (SPAFAS) with escalating doses (x times EID
50) of a current AI strain with HA homology with the H5 or H7 vaccinating strain.
3.2 Assessment of vaccine efficacy by
i) morbidity and mortality in vaccinated vs non-vaccinated chicks
ii) monitoring of AI infection and viral shedding in chicks by detection of viral RNA by AG precipitation & ELISA in cloacal samples
iii) antibody titres from serum samples
4 Manufacture of the vaccine (Bioproperties)Virus (Ad5-H5/H7) culture in human PER 6 cells in serum free suspension bioreactors and chromatographic purification
Formulation of vaccine doses for
in ovodelivery
Commercial automated injector for eggs
5 Field trial under commercial use conditions
Demonstration of clinical efficacy in broilers
Baiada Poultry commercial hatchery and broiler farm
5.1 1000 42 day chicken broiler study of vaccinated vs 1000 normally bred broilers under commercial
hatchery
conditions
5.2 Assessment of vaccine efficacy as per 3.2
5.3 Assessment of vaccine safety (Pharmacology)
5.4 Assessment of environmental impact
Senior management at Chemtech have requested a summary report from the Project Manager on the regulatory requirements associated with the project work described above to assist them in planning execution of the project and to ensure the company is aware of all legal obligations relating to project studies undertaken in house and outsourced to vendors. Management wishes to be fully informed of its legal responsibilities as vaccine developer and contractor. This would include regulatory requirements relating to product approval of the novel vaccine and licenses, permits and accreditations for the listed studies. At this stage management does not require information about the pharmacological evaluation of the vaccine for safety (5.3) and possible environmental impact (5.4).